Wednesday, 21 Feb 2018

You are here

IL-6 Inhibitor Kevzara Granted FDA Approval for Rheumatoid Arthritis

The FDA has approved sarilumab (Kevzara), a new IL-6 inhibitor co-developed by Regeneron and Sanofi's, for use in adults with moderate to severe rheumatoid arthritis (RA).

Although approved in Canada in February 2017, the US submission of the sarilumabs BLA was held up by the FDA with a complete response letter and concerns about manufacturing.

Kevzara is indicated for adult patients with moderate to severe, active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to at least one DMARD. It is and anti-IL-6 receptor targeted therapy.

Sarilumab is off to a unique start with the manufacturers pricing the product 30% lower than TNF inhibitor competitors, and will carry a list price of $39,000 per year for the 200 milligram and 150 mg doses.

FDA approval is based on approximately 2,900 RA patients where it has been shown to yield significant clinical improvement and significantly less radiographic progression compared to placebo plus MTX.

The safety profile of sarilumab appears to be similar to other IL-6 inhibitors studied in RA.

The package insert (http://buff.ly/2rPpTFc) states that the drug is indicated for use as monotherapy or in combination with methotrexate (MTX) or other conventional DMARDs, at a dose of 200 mg once given subcutaneously every two weeks,  It comes with warnings about serious infection, bowel perforations, neutropenia, transaminitis and hyperlipidemia. It requires TB screening prior to use and should not be given with live virus vaccines. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

NHANES Survey Shows OA Rising and RA Declining

An analysis of 43,706 adults from the 1999-2014 National Health and Nutrition Examination Surveys (NHANES) demonstrated temporal trends in the prevalence of arthritis, including a rise in osteoarthritis (OA) from 6.6% to 14.3%, while the prevalence of rheumatoid arthritis (RA) decreased from 5.9% to 3.8% in the USA, (Citation source https://buff.ly/2o6fhkW

DMARDs Lower Dementia Risk in Rheumatoid Arthritis

UK researchers have analyzed rheumatoid arthritis (RA) patients from the UK Clinical Practice Research Database and shown that chronic conventional DMARD (cDMARD) use was associated with 40% lower risk of dementia (nearly 50% with methotrexate use).

Abatacept Shows Promise for RA-ILD

Abatacept (Orencia) may be a useful treatment option for patients with rheumatoid arthritis (RA) who develop interstitial lung disease (ILD), a Spanish study suggested.

Weight Loss Linked to RA Improvement

By retrospectively reviewing electronic health record (EHR) data, Kreps et al found that rheumatoid arthritis (RA) patients who lost >5 kg of weight were three times more likely to demonstrate improvement in disease activity.

Researchers investigated the association between weight loss and CDAI change among patients who were overweight/obese at baseline and who lost weight during follow-up.

IL-1 and IL-6 Inhibition Preferred in Systemic JIA

Since 2000, the German Biologics register (BiKeR) has prospectively enrolled children with juvenile idiopathic arthritis to assess outcomes with biologic therapies.  A new report evaluates the efficacy and safety of etanercept (ETA), tocilizumab (TOC) and the interleukin-1 inhibitors (anakinra and canakinumab) (IL-1i) in those with systemic onset juvenile idiopathic arthritis JIA (sJIA).